CliffBio
small molecule

LEVETIRACETAM

LEVETIRACETAM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameLEVETIRACETAM
Active ingredientLEVETIRACETAM
Strength500MG/5ML (100MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2010
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.